October 2018 Briefing – Urology

Here are what the editors at HealthDay consider to be the most important developments in Urology for October 2018. This roundup includes the latest research news from journal articles, as […]

Here are what the editors at HealthDay consider to be the most important developments in Urology for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Barriers to Prostate Cancer Research in Black Men Identified

WEDNESDAY, Oct. 31, 2018 (HealthDay News) — A lack of understanding of terminology, health care system distrust, and a lack of prostate cancer knowledge are among the barriers to genomic testing for prostate cancer and prostate cancer research participation among black men, according to a study published in the November issue of the American Journal of Preventive Medicine.

Abstract/Full Text

Erectile Dysfunction Common in Childhood Cancer Survivors

TUESDAY, Oct. 30, 2018 (HealthDay News) — The prevalence of erectile dysfunction (ED) is 29 percent among male childhood cancer survivors (CCS), according to a research letter published online Oct. 4 in JAMA Oncology.

Abstract/Full Text (subscription or payment may be required)

AMA Announces Initiative to Reinvent Physician Training

TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.

More Information

Many Hospitals Noncompliant With Record Request Regulations

MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.

Abstract/Full Text

In Complicated UTI, Cefiderocol Noninferior to Imipenem-Cilastin

MONDAY, Oct. 29, 2018 (HealthDay News) — For complicated urinary tract infections caused by multidrug-resistant Gram-negative uropathogens, the siderophore cephalosporin cefiderocol is non-inferior to imipenem-cilastatin, according to a study published online Oct. 25 in The Lancet Infectious Diseases.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Hypofractionated Radiation OK for Localized Prostate CA

MONDAY, Oct. 29, 2018 (HealthDay News) — A new clinical guideline for early-stage prostate cancer supports the use of shortened courses of radiation therapy, according to an article published in Practical Radiation Oncology.

Abstract/Full Text

Trump Administration Announces Plan to Cut Drug Prices

FRIDAY, Oct. 26, 2018 (HealthDay News) — In an effort to cut high drug costs, the prices paid by Medicare for certain prescription drugs would be based on those in other advanced industrial nations, according to a proposal announced Oct. 25 by the Trump administration.

HHS Study
New York Times Article

Outcomes Studied for Surgical Tx of Stress Urinary Incontinence

1 | 2 | 3 | 4
Page 1 of 4
Next »
Top 15 Online Casinos in Österreich mit Echtgeld 2025
casino-admiral-legale-online-casino-fur-osterreichische-spieler-mit-echter-spielgarantie